Michael Trauner Selected Research

Sclerosing Cholangitis

6/2022	IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
1/2022	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
1/2022	Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis via immunomodulatory effects.
11/2021	24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation.
1/2020	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
1/2020	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
1/2019	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
10/2018	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy.
1/2018	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
1/2018	Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Trauner Research Topics

Disease

125	Fibrosis (Cirrhosis) 12/2022 - 12/2005
97	Liver Diseases (Liver Disease) 10/2022 - 05/2002
84	Cholestasis 12/2022 - 01/2002
62	Inflammation (Inflammations) 01/2022 - 04/2005
48	Liver Cirrhosis (Hepatic Cirrhosis) 11/2022 - 11/2004
47	Non-alcoholic Fatty Liver Disease 10/2022 - 01/2010
40	Portal Hypertension 10/2022 - 07/2011
39	Hepatocellular Carcinoma (Hepatoma) 05/2022 - 04/2005
35	Sclerosing Cholangitis 06/2022 - 05/2003
29	Neoplasms (Cancer) 11/2021 - 04/2005
28	Fatty Liver 11/2022 - 02/2009
25	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 06/2022 - 05/2002
21	Infections 02/2022 - 05/2004
20	End Stage Liver Disease 10/2021 - 11/2009
15	Hemorrhage 12/2022 - 11/2013
14	Disease Progression 01/2022 - 11/2010
14	Insulin Resistance 05/2021 - 01/2010
12	Ascites 07/2022 - 01/2014
11	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2020 - 01/2012
9	Hepatitis C 04/2022 - 03/2015
9	Chronic Hepatitis C 01/2018 - 04/2003
8	Intrahepatic Cholestasis of Pregnancy 01/2020 - 02/2002
8	Critical Illness (Critically Ill) 01/2019 - 01/2012
8	Carcinogenesis 01/2016 - 01/2007
7	Liver Failure 12/2022 - 10/2003
7	Sepsis (Septicemia) 05/2021 - 05/2004
7	Cholangitis 02/2020 - 02/2006
6	COVID-19 12/2022 - 01/2020
6	Obesity 11/2022 - 08/2015
6	Alcoholic Fatty Liver 11/2022 - 11/2004
6	Pruritus (Itching) 06/2022 - 04/2005
6	Liver Neoplasms (Liver Cancer) 04/2022 - 01/2007
6	Varicose Veins (Varicose Vein) 04/2022 - 11/2013
6	Acute Liver Failure (Fulminant Hepatic Failure) 01/2022 - 10/2003
6	Acute-On-Chronic Liver Failure 01/2022 - 03/2007
6	Cholelithiasis 01/2022 - 05/2002
6	Cystic Fibrosis (Mucoviscidosis) 03/2020 - 01/2008
5	Anemia 12/2022 - 07/2011
5	Jaundice (Icterus) 02/2021 - 04/2005
5	Hepatitis 01/2021 - 08/2005
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 02/2010

Drug/Important Bio-Agent (IBA)

93	Bile Acids and Salts (Bile Acids)IBA 01/2022 - 01/2002
30	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/2020 - 05/2002
27	LipidsIBA 11/2022 - 01/2007
27	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022 - 05/2004
23	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2005
21	Biomarkers (Surrogate Marker)IBA 11/2022 - 08/2005
19	Pharmaceutical PreparationsIBA 01/2017 - 05/2002
18	BilirubinIBA 12/2022 - 04/2005
17	EnzymesIBA 01/2022 - 04/2005
17	LigandsIBA 01/2022 - 05/2004
16	CytokinesIBA 01/2020 - 03/2005
15	Triglycerides (Triacylglycerol)IBA 02/2021 - 02/2010
14	InterferonsIBA 04/2022 - 07/2011
14	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2011
13	RNA (Ribonucleic Acid)IBA 11/2022 - 01/2012
13	4-(3-chlorophenylsulfanyl)piperidineIBA 02/2022 - 07/2011
11	Alkaline PhosphataseIBA 12/2022 - 08/2008
11	AcidsIBA 10/2019 - 06/2009
10	Phospholipases (Phospholipase)IBA 01/2022 - 01/2012
10	von Willebrand FactorIBA 01/2022 - 10/2012
10	C-Reactive ProteinIBA 01/2022 - 06/2013
10	CholesterolIBA 11/2019 - 05/2002
9	AlbuminsIBA 04/2022 - 10/2016
9	Messenger RNA (mRNA)IBA 01/2022 - 06/2006
9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2011
9	Hydroxyproline (4 Hydroxyproline)IBA 01/2021 - 08/2008
9	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020 - 01/2004
8	Immunoglobulin G (IgG)IBA 04/2022 - 03/2012
8	Alanine Transaminase (SGPT)IBA 02/2020 - 04/2015
8	Taurocholic Acid (Sodium Taurocholate)IBA 01/2018 - 01/2002
7	gadolinium ethoxybenzyl DTPA FDA Link 10/2022 - 06/2014
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 07/2012
7	24-norursodeoxycholic acidIBA 11/2021 - 02/2006
7	obeticholic acidIBA 01/2020 - 10/2011
6	CollagenIBA 11/2022 - 02/2015
6	Transaminases (Aminotransferases)IBA 04/2022 - 09/2007
6	LipopolysaccharidesIBA 01/2022 - 10/2009
6	Therapeutic UsesIBA 12/2021 - 06/2009
6	AntibodiesIBA 01/2021 - 03/2009
6	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 06/2012
6	Peptides (Polypeptides)IBA 01/2020 - 10/2007
6	CopperIBA 05/2019 - 11/2004
6	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 07/2011
6	Adenosine Triphosphate (ATP)IBA 10/2017 - 09/2003
6	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2017 - 09/2003
5	selonsertibIBA 01/2022 - 11/2019
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 08/2011
5	AntigensIBA 12/2021 - 10/2012
5	Interleukin-6 (Interleukin 6)IBA 12/2021 - 04/2013
5	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 03/2005
5	Hormones (Hormone)IBA 10/2021 - 04/2005
5	SodiumIBA 01/2021 - 10/2007

Therapy/Procedure

57	Therapeutics 06/2022 - 04/2003
35	Liver Transplantation 11/2021 - 10/2003
17	Ligation 01/2022 - 06/2006
10	Transjugular Intrahepatic Portasystemic Shunt 12/2022 - 09/2017
7	Drug Therapy (Chemotherapy) 01/2021 - 04/2005
6	Surgical Portasystemic Shunt (Portosystemic Shunt) 12/2022 - 12/2017
5	Transplantation 02/2020 - 10/2012